 MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 GLOBE NEWSWIRE -- Adicet Bio, Inc. Nasdaq: ACET, a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. 